1029720-19-1

Basic information

• Product Name: tert-butyl 3,3-difluorocyclobutylcarbaMate
• Synonyms: tert-butyl 3,3-difluorocyclobutylcarbaMate;Carbamic acid, N-(3,3-difluorocyclobutyl)-,1,1-dimethylethyl ester;N-(3,3-Difluorocyclobutyl)carbamic acid 1,1-dimethylethyl ester;tert-butyl n-(3,3-difluorocyclobutyl)carbamate
• CAS NO: 1029720-19-1
• Molecular Formula: C9H15F2NO2
• Molecular Weight: 207.2177064
• Mol File: 1029720-19-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 254.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• PKA: 10.68±0.40(Predicted)
• CAS DataBase Reference: tert-butyl 3,3-difluorocyclobutylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3,3-difluorocyclobutylcarbaMate(1029720-19-1)
• EPA Substance Registry System: tert-butyl 3,3-difluorocyclobutylcarbaMate(1029720-19-1)

Safety Data

• Hazardous Substances Data: 1029720-19-1(Hazardous Substances Data)

Usage

General Description

"Tert-butyl 3,3-difluorocyclobutylcarbaMate" is a chemical compound with a molecular formula C9H15F2NO2. It is a carbamate derivative that contains a tert-butyl group and a 3,3-difluorocyclobutyl group. tert-butyl 3,3-difluorocyclobutylcarbaMate is a potential drug candidate with possible pharmaceutical applications. The tert-butyl group provides stability to the molecule, while the 3,3-difluorocyclobutyl group may impart specific biological activity. Further research and testing are needed to fully understand the properties and potential uses of this compound in the pharmaceutical industry.

Upstream product

• 791061-00-2 3,3-difluorocyclobutyl-1-amine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 107496-54-8 3,3-difluorocyclobutanecarboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 

Downstream Products

• 1355328-30-1 N-(3,3-difluorocyclobutyl)formamide 
• 1448348-04-6 (4S)-N-(1-(2-Chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluoro-phenyl)-2-oxooxazolidine-4-carboxamide 
• 1448345-75-2 (S)-N-((R)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluorophenyl)-2-oxo-3-(pyrimidin-2-yl)oxazolidine-4-carboxamide 
• 1448348-05-7 (S)-N-(1-(2-Chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluoro-phenyl)-6-oxopiperidine-2-carboxamide 
• 1448348-25-1 (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide 
• 1448346-14-2 (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxo-4-(pyrimidin-2-yl)morpholine-3-carboxamide 
• 1448348-39-7 5-((2S)-N-(1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyano pyridin-2-yl)-5-oxopyrrolidine-2-carboxamido)isophthalamide 
• 1448347-64-5 (2S)-N-(1-(2-Chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(3,5-dicyanophenyl)-5-oxopyrrolidine-2-carboxamide 
• 637031-93-7 3,3-difluorocyclobutylamine hydrochloride 
• 1448348-13-7 (2S)-4-(tert-Butyldimethylsilyloxy)-N-(1-(2-chlorophenyl)-2-(3,3-difluorocyclobut-ylamino)-2-oxoethyl)-N-(3-fluorophenyl)-4-methyl-5-oxopyrrolidine-2-carboxamide 
• 1448348-14-8 (2S)-4-(tert-Butyldimethylsilyloxy)-N-(1-(2-chlorophenyl)-2-(3,3-difluorocyclobutyl-amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-4-methyl-5-oxopyrrolidine-2-carboxamide 
• 1448348-22-8 (4S)-N-(1-(2-Chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluoro-phenyl)-1-methyl-2-oxoimidazolidine-4-carboxamide 
• 1448348-21-7 Ethyl 2-((4S)-4-((1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)(3-fluorophenyl)carbamoyl)-2-oxoimidazolidin-1-yl)acetate 
• 1448310-13-1 (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluorophenyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

The invention relates to a ROCK inhibitor represented by formula (I), its preparation method and its use. The ROCK inhibitor has excellent ROCK inhibition activity, in particular good selective inhibition on ROCK2 kinase, has good safety and metabolic stability, and has high bioavailability. The process of preparing the ROCK inhibitor is simple, and the ROCK inhibitor is easy to purify, and therefore offers good prospects for application.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

Lead Optimization toward Proof-of-Concept Tools for Huntington's Disease within a 4-(1 H -Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole. (Chemical Presented)